Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Newswire

Comprehensive Real-Time News Feed for Teva Pharmaceutical Industries.

Results 1 - 20 of 474 in Teva Pharmaceutical Industries

  1. Net Expense Ratio Reductions Announced for Appleseed Fund Investor, Institutional SharesRead the original story w/Photo

    37 min ago | Business Wire

    Appleseed Fund , has announced expense-ratio reductions for its Investor and Institutional share classes, effective Oct. 1, 2014. "As we begin a new fiscal year Oct. 1, we will be trimming four basis points off Appleseed Fund Investor shares, resulting in a 1.20% net expense ratio.

    Comment?

  2. Protalix Biotherapeutics, Inc. Appoints As President And CEORead the original story

    Yesterday | BioSpace

    ... and the innovative pharmaceutical world, from his years as Executive Vice President at Teva Pharmaceutical Industries. His talents and experience, will be helpful in further managing Protalix. We look forward to his leadership as Chief Executive ...

    Comment?

  3. Teva Pharmaceutical Industries Ltd Receives Consensus Recommendation...Read the original story w/Photo

    22 hrs ago | AmericanBankingNews.com

    Teva Pharmaceutical Industries Ltd has been given an average rating of "Buy" by the twenty-five brokerages that are currently covering the company, American Banking News.com reports . Seven investment analysts have rated the stock with a hold recommendation, twelve have given a buy recommendation and one has given a strong buy recommendation to the company.

    Comment?

  4. "Women Infertility - Pipeline Review, H2 2014" PublishedRead the original story

    Yesterday | PR-inside.com

    ... plc, Merck & Co., Inc., Reliance Life Sciences Pvt. Ltd., ASKA Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Limited, Zydus Cadila Healthcare Limited, Ferring International Center S.A., Pantec Biosolutions AG, Access Pharmaceuticals, ...

    Comment?

  5. Indian stock market and companies daily reportRead the original story

    Yesterday | Stock Market Review

    Indian markets are expected to open negative tracking SGX Nifty and Asian markets. US index jumped as data showed US economy expanded in the second quarter at the fastest pace since last quarter of 201 1, as companies stepped up investment and household boosted spending.

    Comment?

  6. What This Huge George Soros Mistake Can Teach YouRead the original story w/Photo

    Saturday Sep 27 | The Motley Fool

    ... example will help to clarify this point. The Soros Fund Management had been heavily buying Teva Pharmaceutical Industries ( ) all the way through the first-quarter of 2014, making it the fund's largest position at one point. A look at the historical ...

    Comment?

  7. Rexahn Update: A Partnership Is All The More LikelyRead the original story w/Photo

    Thursday Sep 25 | Seeking Alpha

    I reiterate my bull thesis since this likely increases the commercial value of RX-3117. It also gives Rexahn more leverage when entering a licensing agreement.

    Comment?

  8. Is It Time to Buy Dividend Stock Teva Pharmaceutical Industries Ltd?Read the original story

    Thursday Sep 25 | The Motley Fool

    Dividend stocks are a pivotal part of a balanced portfolio because they provide income and can help to lower the average purchase price of shares over time through dividend reinvestment plans. ) is a core holding in a number of high-profile funds because the stock offers a decent 2.27% yield and looks fundamentally undervalued on multiple fronts.

    Comment?

  9. Global and Chinese Betamethasone Dipropionate Industry 2009-2019 Research ReportRead the original story

    Thursday Sep 25 | Emailwire.com

    ... (Including Company Profile, Product Specification, 2009-2014 Production Information etc.) 3.1 Teva Pharmaceutical Industries Ltd. Chapter Four 2009-2014 Global and China Market of Betamethasone dipropionate 4.1 2009-2014 Global and China Capacity, ...

    Comment?

  10. Montelukast Sodium Industry 2009-2019 Research Report for Global and ChinaRead the original story

    Thursday Sep 25 | Emailwire.com

    ... (Including Company Profile, Product Specification, 2009-2014 Production Information etc.) 3.1 Teva Pharmaceutical Industries Ltd. Chapter Four 2009-2014 Global and China Market of Montelukast sodium 4.1 2009-2014 Global and China Capacity, ...

    Comment?

  11. Global and Chinese Formoterol fumarate Industry 2009-2019 Research ReportRead the original story

    Thursday Sep 25 | Emailwire.com

    ... (Including Company Profile, Product Specification, 2009-2014 Production Information etc.) 3.1 Teva Pharmaceutical Industries Ltd. Chapter Four 2009-2014 Global and China Market of Formoterol fumarate 4.1 2009-2014 Global and China Capacity, ...

    Comment?

  12. Safeguard Scientifics to Release Third Quarter 2014 Financial Results on Friday, October 24thRead the original story w/Photo

    Wednesday Sep 24 | PRWeb

    ... Crescendo Bioscience (acquired by Myriad Genetics for $270 million); NuPathe (acquired by Teva Pharmaceutical Industries for $144 million); and ThingWorx (acquired by PTC for initial proceeds of $112 million). For more information, please visit ...

    Comment?

  13. Teva: On The Auction Block?Read the original story w/Photo

    Tuesday Sep 23 | Seeking Alpha

    Teva reported in-line second-quarter results . The firm had a rough start shortly after it was added to the Best Ideas portfolio, but recent performance has put holders well into the black .

    Comment?

  14. Reckitt files patent infringement case against Aurobindo PharmaRead the original story w/Photo

    Monday Sep 22 | Express India

    The infringement was on Guaifenesin sustained release formulation and tablets issued during 2002, 2005, and 2010 following a Paragraph IV certification as part of Aurobindo's filing of an ANDA to manufacture a generic version of the plaintiff's Mucinex and Mucinex used to treat chest congestion. Meanwhile, in a similar patent infringement case, Israel-based Teva Pharmaceutical Industries has filed litigations against Sandoz, Momenta Pharmaceuticals and Dr Reddy's Laboratories in the US District Court of Delaware.

    Comment?

  15. Shift work: Marketing medication for symptoms instead of addressing the hazardRead the original story

    Monday Sep 22 | ScienceBlogs

    ... the website designed to market the drug known as Nuvigil , sold by Cephalon , a subsidiary of Teva Pharmaceutical Industries, Ltd. Approved by the US Food and Drug Administration (FDA) in 2007 to treat narcolepsy and obstructive sleep apnea and the ...

    Comment?

  16. Natco Pharma Limited, Hit With A Strong Dose Of FDA MedicineRead the original story

    Friday Sep 19 | BioSpace

    Posted: September 18, 2014 4:35 am Natco Pharma and Orchid Chemicals and Pharmaceuticals have received an adverse observation report, commonly known as Form 483, after inspections conducted in their manufacturing units earlier this year by the US Food and Drug Administration, according to documents reviewed by FE. Natco, which was in news for battling Teva Pharmaceutical Industries over the patent of the latter's multiple sclerosis drug Copaxone, was issued the Form 483 dated May 23 after a five-day inspection of its finished dosage facility located in Mahabubnagar district in Telangana.

    Comment?

  17. New market study, "PLIVA d.d. - Strategic SWOT Analysis Review", has been publishedRead the original story

    Thursday Sep 18 | PR-inside.com

    PLIVA is a subsidiary of Teva Pharmaceutical Industries Limited. The company offers wide variety of products including cardiovascular, gastrointestinal, anti-infectives, oncology, musculoskeletal, neurological and psychiatric diseases.

    Comment?

  18. Natco Pharma, Orchid get a strong dose of Us Fda medicineRead the original story w/Photo

    Wednesday Sep 17 | The Indian Express

    Natco Pharma and Orchid Chemicals and Pharmaceuticals have received an adverse observation report, commonly known as Form 483, after inspections conducted in their manufacturing units earlier this year by the US Food and Drug Administration, according to documents reviewed by FE. Natco, which was in news for battling Teva Pharmaceutical Industries over the patent of the latter's multiple sclerosis drug Copaxone, was issued the Form 483 dated May 23 after a five-day inspection of its finished dosage facility located in Mahabubnagar district in Telangana.

    Comment?

  19. Summary of Research Progress Reported at the World's Largest MS MeetingRead the original story

    Wednesday Sep 17 | PressReleasePoint

    ... Synthon BV) reduced disease activity on MRI scans similarly to CopaxoneA (glatiramer acetate, Teva Pharmaceutical Industries Ltd). Participants were randomly assigned to receive GTR (20 mg/day injected under the skin), Copaxone (20 mg/day injected ...

    Comment?

  20. Successful Completion of Phase III Program for Teva's Reslizumab Two...Read the original story

    Wednesday Sep 17 | Hispanic Business

    The data demonstrated that reslizumab treatment resulted in significant improvement in lung function and asthma control measures and showed a safety profile comparable to placebo . Reslizumab treatment resulted in significant improvements in lung function versus placebo when administered to patients, with moderate to severe asthma with elevated eosinophils.

    Comment?